MRC1 and colorectal cancer: The standard of care for patients with colorectal cancer remains adjuvant combined chemotherapy that includes the nucleoside inhibitor 5-FU, even though multiple clinical studies have now shown that MMR-deficient tumors might not benefit from 5-FU treatment (reviewed in 4,27).